| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5127 | Thielocin B1 | Novel protein-protein interaction inhibitor of PAC3 homodimer |
|
| DCC5128 | Thiobenzanilide 63t | Novel selective anticancer agent, selectively inducing cancer cell death in a caspase independent pathway |
|
| DCC5129 | Thiocrom-31 | First-in-class potent, selective, reversible, and tight binding inhibitor of human monoamine oxidase B (hMAO-B) (hMAO-B IC 50 = 1.52 ± 0.15 nM) |
|
| DCC5130 | Thioguanine-18 | Novel potent DENV2-NS2B/NS3pro inhibitor |
|
| DCC5131 | Thioluciferin | Firefly luciferin analog as a key element of bioluminescent reporters for oxidation state and thiol/disulfide equilibria |
|
| DCC5132 | Thiomuscimol Hydrobromide | GABAA receptor agonist |
|
| DCC5133 | Thiowurtzine | Novel Potent Inhibitor of the Opioid Receptors and the Ion Channels |
|
| DCC5134 | Thioxodihydroquinazolinone-19 | Novel inducer of apoptotic cell death in platinum-resistant A2780cis human ovarian cancer cells, exhibitong a strong inhibitory effect in ovarian CSC-LCs in combination with cisplatin |
|
| DCC5135 | Thiq-20c | Steroidomimetic and Chimeric Microtubule Disruptor |
|
| DCC5136 | Thk-523 | Selective Tau ligand, selectively binding to neurofibrillary tangles and neuropils in people with Alzheimer's disease |
|
| DCC5137 | Th-pf01 | Novel orthosteric-allosteric dual inhibitor of PfHT1 as selective antimalarial agent |
|
| DCC5138 | Th-pf02 | Novel orthosteric-allosteric dual inhibitor of PfHT1 as selective antimalarial agent |
|
| DCC5139 | Th-pf03 | Novel orthosteric-allosteric dual inhibitor of PfHT1 as selective antimalarial agent |
|
| DCC5140 | Thpp-11f | Novel potent, highly selective and orally available PI3Kδ inhibitor |
|
| DCC5141 | Thpp-2 | Novel phosphodiesterase 10A (PDE10A) inhibitor for treatment of schizophrenia |
|
| DCC5142 | Thpp-4 | Phosphodiesterase 10A (PDE10A) inhibitor |
|
| DCC5143 | Thr101 | Novel dose-dependent inhibitor of HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9; NOX Inhibitor |
|
| DCC5144 | Thrombin-in-3g | Novel selective thrombin inhibitor, inducing conformational allostery |
|
| DCC5145 | Thrx160209 | Novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor |
|
| DCC5146 | Tiagabine | Anti-epileptic and anticonvulsant agent, acting as a selective GABA reuptake inhibitor |
|
| DCC5147 | Tiancimycin | Anthraquinone-fused enediyne antitumor agent for development of antibody-drug conjugates (ADCs) |
|
| DCC5148 | Tiemonium Iodide | Muscarinic receptor antagonist, anticholinergic,and parasympatholytic |
|
| DCC5149 | Tigilanol Tiglate | Natural anticancer agent fortreatment of mast cell tumor (MCT) |
|
| DCC5150 | Tillman Reagent | Widely used oxidation-reduction indicator |
|
| DCC5151 | Tilmicosin Phosphate | Macrolide antibiotic for the treatment of bovine respiratory disease and ovine respiratory disease associated with Mannheimia (Pasteurella) haemolytica |
|
| DCC5152 | Tilorone Dihydrochloride | Antiviral, antineoplastic, and anti-inflammatory agent; Orally active interferon inducer, inhibiting Ebola virus (EBOV) |
|
| DCC5153 | Tinostamustine Hydrochloride | Novel pan-histone-deacetylase inhibitor with alkylating activity |
|
| DCC5154 | Tinyatoxin | Neurotoxin, acting via vanilloid receptors of sensory nerves |
|
| DCC5155 | Tioxolone | Novel hepcidin antagonist |
|
| DCC5156 | tipp-204 | hPPAR |
|
